Zolpidem CR
ApprovedSmall molecule
Zolpidem CR is one of 59 small molecule programs targeting Suicidal Ideation. It is currently in Approved.
2
Indications
4
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Dementia
#DrugCompanyPhaseTrials
1Leqembi
EisaiPhase 3
Depacon
AbbViePhase 3
Abilify
OtsukaPhase 3
Glucophage
EMD SeronoPhase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Aricept
EisaiPhase 3
Seroquel
AstraZenecaPhase 3
Aleve
Alnylam PharmaceuticalsPhase 2
Depakote ER
Mylan Pharmaceuticals IncPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Suicidal Ideation1 trial
Reducing Suicidal Ideation Through Insomnia Treatment
Completed·—·Phase 4·NCT01689909·103 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zolpidem CR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMassachusetts General Hospital